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Abstract: Ovarian cancer is the most lethal gynecologic malignancy, and patient prognosis has not
improved significantly over the last several decades. In order to improve therapeutic approaches
and patient outcomes, there is a critical need for focused research towards better understanding of
the disease. Recent findings have revealed that the tumor microenvironment plays an essential role
in promoting cancer progression and metastasis. The tumor microenvironment consists of cancer
cells and several different types of normal cells recruited and reprogrammed by the cancer cells
to produce factors beneficial to tumor growth and spread. These normal cells present within the
tumor, along with the various extracellular matrix proteins and secreted factors, constitute the tumor
stroma and can compose 10–60% of the tumor volume. Cancer associated fibroblasts (CAFs) are
a major constituent of the tumor microenvironment, and play a critical role in promoting many
aspects of tumor function. This review will describe the various hypotheses about the origin of CAFs,
their major functions in the tumor microenvironment in ovarian cancer, and will discuss the potential
of targeting CAFs as a possible therapeutic approach.
Keywords: ovarian cancer; tumor microenvironment; cancer associated fibroblasts; fibroblast;
cross-talk; invasion; angiogenesis; ECM; chemoresistance; therapy
1. Introduction
Ovarian cancer is the deadliest of all the gynecologic malignancies, and is the fifth leading cause of
cancer related deaths among women in the United States. There has been only a modest improvement
in ovarian cancer patient prognosis over the last several decades [1,2]. Therefore, there is a critical need
for focused research to improve our understanding of the disease and develop novel therapies that are
more effective. In the past, most of the research efforts were focused on the cancer cells in isolation.
However, recent research has identified the tumor microenvironment as a key factor in promoting
cancer progression [3–7]. The cancer cells recruit various normal cells and reprogram them to produce
factors beneficial to tumor growth and spread. These normal cells present within the tumor constitute
the tumor stroma and can compose 10–60% of the tumor volume [3].
In order to survive and proliferate, the cancer cells productively interact with their
microenvironment. The tumor microenvironment is complex and contains a variety of cells constituting
the tumor stroma. Tumors however, can only grow if their complex tissue environment provides them
with a milieu of factors and conditions that can sustain their growth and spread [8]. A complicated
bidirectional interaction is therefore happening at the interface between the genetically unstable
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malignant cells and the genetically stable stroma, a process that will determine the degree of tumor
promotion and proliferation, invasiveness, potential for spread, and even patient prognosis [9].
The tumor stroma consists of cellular components like the cancer associated fibroblasts (CAFs),
immune cells, endothelial cells, pericytes, adipocytes, and so forth, as well as acellular components
like the extra cellular matrix proteins (ECMs) [3–7]. Each of these tumor microenvironmental elements
has been shown to play important roles in tumor growth and progression in various cancers, including
ovarian cancer. CAFs are an important constituent of the tumor stroma, and this review will
focus on providing an overview of the origin, function, and potential targeting of CAFs in ovarian
cancer therapy.
2. Origin of CAFs
There are several hypotheses about the origin of CAFs, which include the reprogramming of
the resident normal fibroblasts by the cancer cells, and differentiation of mesenchymal stem cells
(Figure 1). A less widely accepted theory is that they are already present as a small subpopulation
of normal fibroblasts, which are selected for by the cancer cells [10]. These subpopulations may
have acquired a mutation, or epigenetic alterations, independent of the tumor cells, which transform
them into activated fibroblasts. A proinflammatory microenvironment resulting in the generation of
reactive oxygen species may promote acquisition of genetic lesions [11]. As the tumor develops in
their vicinity, these subpopulations might be selected for by the cancer cells for their ability to support
tumor growth [10]. Since mutations are not commonly found in the tumor stroma, and CAFs are not
believed to have clonal populations with distinct genetic changes, this hypothesis has not gained much
traction [12]. Fibroblasts are mesenchymal cells that are generally present in the basement membrane
and serve as a scaffold, secreting ECMs, and growth and trophic factors [13,14]. They are generally
in a quiescent “inactive” state, but retain some plasticity, and are capable of getting “activated”
by various physiological stimuli. During development, dermal fibroblasts play a role in tissue
patterning, and can differentiate into multiple kind of cells, including hair follicle cells, papillary
cells, reticular cells, and pre-adipocytes [15]. The fibroblasts get activated at the site of wound
healing by factors such as insulin-like growth factors (IGFs), transforming growth factor beta 1,2,3
(TGF-β 1,2,3), and platelet-derived growth factor (PDGF), among others. These activated fibroblasts
express α-smooth muscle actin (α-SMA), which makes them contractile, and helps in wound closure.
These α-SMA expressing fibroblasts are called myofibroblasts. They secrete various ECMs and
extracellular proteases, which help in the initial wound healing and development of the scar. They also
secrete factors like TGF-β to stimulate epithelial to mesenchymal transition in the epithelial cells
around the wound. This enables the epithelial cells to move and close the wound. Thereafter, as the
wound heals, epithelialization is promoted by epidermal growth factors (EGFs) and the keratinocyte
growth factor (KGF) produced by the fibroblasts [16].
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Figure 1. Formation of cancer associated fibroblasts (CAFs) through the reprogramming of resident 
normal fibroblasts or mesenchymal stem cells by ovarian cancer cells. TGF‐β: transforming growth 
factor  beta; PDGF: platelet‐derived  growth  factor;  FGF:  fibroblast  growth  factor; EGF:  epidermal 
growth factors; CXCL12: C‐X‐C Motif Chemokine Ligand 12; CCL5: C‐C Motif Chemokine Ligand 5; 
↑: upregulated;↓: downregulated. 
CAFs display  several  traits  of  the  activated  fibroblasts  found  in  healing wounds,  including 
upregulation of TGF‐β, increased secretion of ECMs, extra cellular proteases, and expression of α‐
SMA. It is believed that cancer cells can recruit the resident normal fibroblasts and reprogram them 
into CAFs. Several  reports have demonstrated  evidence  in  support of  this hypothesis  in ovarian 
cancer [7]. Ovarian cancer cells produce factors including TGF‐β and PDGF, that can change normal 
fibroblasts into “activated” CAFs. We have previously shown that ovarian cancer cells can induce a 
change  in  expression of a  set of 3 microRNAs  in  the  resident normal omental  fibroblasts, which 
reprograms  them  into  CAFs  [7].  miR‐214  and  miR‐31  were  found  to  decrease,  while  miR‐155 
expression  increased,  in  the normal  fibroblasts because of  their  interaction with  the metastasizing 
ovarian cancer cells. This resulted in their reprogramming into CAFs (Figure 1). It was the first report 
of a set of microRNAs reprogramming normal fibroblasts into CAFs. Simultaneous inhibition of miR‐
214 and miR‐31, along with overexpression of miR‐155, could convert normal fibroblasts into CAFs. 
These  results  supported  previous  findings  in  other  cancers, which  demonstrated  the  absence  of 
mutations in CAFs. Moreover, CAFs can be isolated from tumors and cultured in vitro for several 
passages,  and  yet  retain  their  phenotype  and  their  ability  to  support  cancer  cell  functions. This 
suggested a potential role of epigenetic regulation [17]. The role of microRNAs in reprogramming of 
normal fibroblasts into CAFs further revealed a potential mechanism. Interestingly, overexpressing 
miR‐214 and miR‐31 and  inhibiting miR‐155 simultaneously  in CAFs could revert  them back  into 
normal fibroblasts. This offers a potential opportunity to normalize a key component of the tumor 
microenvironment.  Research  on  targeting  the  tumor  microenvironment  has  revealed  that  the 
normalization of the tumor microenvironment is a more effective approach as compared to attempts 
at obliterating it altogether. The latter typically leads to the cancer cells becoming more aggressive. 
Depleting α‐SMA positive CAFs in a transgenic mouse model of pancreatic ductal adenocarcinoma 
through  induction  of  thymidine  kinase  by  ganciclovir  administration,  either  early  in  the  tumor 
precursor stage or late carcinoma stage, led to the development of undifferentiated tumors, which 
were highly invasive and resulted in decreased survival [18]. Since this was observed when the CAFs 
were ablated in the precursor lesions or in the late carcinomas, it indicated that irrespective of tumor 
stage, in the absence of the microenvironmental support, the more aggressive cancer cell clones are 
selected. These findings are similar to the increased metastasis observed upon pericyte depletion [19]. 
Other hypotheses about the origin of CAFs include the recruitment of mesenchymal stem cells 
by the cancer cells to the tumor [10,20]. Human pancreatic cancer cells were shown to recruit bone 
i re 1. r ati f ca cer ass ciate fi r lasts ( s) t r t e re r ra i f resi e t
nor al fibroblasts or esenchy al ste cells by ovarian cancer cells. TGF-β: transfor ing gro th
factor beta; P F: platelet-derived gro th factor; F F: fibroblast gro th factor; E F: epider al
gro th factors; CXCL12: C-X-C Motif Chemokine Ligand 12; CCL5: C-C Motif Chemokine Ligand 5; ↑:
upregulated;↓: downregulated.
CAFs display several traits of the activated fibroblasts found in healing wounds, including
upregulation of TGF-β, increased secretion of ECMs, extra cellular proteases, and expression of α-SMA.
It is believed that cancer cells can recruit the resident normal fibroblasts and reprogram them into
CAFs. Several reports have demonstrated evidence in support of this hypothesis in ovarian cancer [7].
Ovarian cancer cells produce factors including TGF-β and PDGF, that can change normal fibroblasts
into “activated” CAFs. We have previously shown that ovarian cancer cells can induce a change in
expression of a set of 3 microRNAs in the resident normal omental fibroblasts, which reprograms
them into CAFs [7]. miR-214 and miR-31 were found to decrease, while miR-155 expression increased,
in the normal fibroblasts because of their interaction with the metastasizing ovarian cancer cells.
This resulted in their reprogramming into CAFs (Figure 1). It was the first report of a set of microRNAs
reprogramming normal fibroblasts into CAFs. Simultaneous inhibition of miR-214 and miR-31, along
with overexpression of miR-155, could convert normal fibroblasts into CAFs. These results supported
previous findings in other cancers, which demonstrated the absence of mutations in CAFs. Moreover,
CAFs can be isolated from tumors and cultured in vitro for several passages, and yet retain their
phenotype and their ability to support cancer cell functions. This suggested a potential role of
epigenetic regulation [17]. The role of microRNAs in reprogramming of normal fibroblasts into
CAFs further revealed a potential mechanism. Interestingly, overexpressing miR-214 and miR-31
and inhibiting miR-155 simultaneously in CAFs could revert them back into normal fibroblasts.
This offers a potential opportunity to normalize a key component of the tumor microenvironment.
Research on targeting the tumor microenvironment has revealed that the normalization of the tumor
microenvironment is a more effective approach as compared to attempts at obliterating it altogether.
The latter typically leads to the cancer cells becoming more aggressive. Depleting α-SMA positive CAFs
in a transgenic mouse model of pancreatic ductal adenocarcinoma through induction of thymidine
kinase by ganciclovir administration, either early in the tumor precursor stage or late carcinoma
stage, led to the development of undifferentiated tumors, which were highly invasive and resulted
in decreased survival [18]. Since this was observed when the CAFs were ablated in the precursor
lesions or in the late carcinomas, it indicated that irrespective of tumor stage, in the absence of the
microenvironmental support, the more aggressive cancer cell clones are selected. These findings are
similar to the increased metastasis observed upon pericyte depletion [19].
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Other hypotheses about the origin of CAFs include the recruitment of mesenchymal stem cells by
the cancer cells to the tumor [10,20]. Human pancreatic cancer cells were shown to recruit bone marrow
derived progenitors when injected in mice [21]. The resulting tumors had about 40% myofibroblasts
derived from bone marrow cells. Similarly, CAFs were shown to be derived from mesenchymal
stem cells in ovarian cancer and supported tumor growth through the secretion of the paracrine
factor IL-6 [22]. Ovarian cancer cells have been reported to secrete IL-1β that leads to the decreased
expression of p53 protein in the ovarian fibroblasts, converting them into CAFs [23]. The decreased
p53 resulted in increased secretion of IL-8, growth regulated oncogene-alpha (GRO-α), IL-6, IL-1β,
and vascular endothelial growth factor (VEGF) by the CAFs. Mesenchymal stem cell derived CAFs
were also shown to regulate ovarian cancer stem cells through bone morphogenetic protein secretion,
which resulted in resistance to chemotherapy [24,25]. The mesothelial cells lining the peritoneum and
the omentum have also been reported as a source of CAFs in ovarian cancer peritoneal and omental
metastasis [26]. The mesothelial cells have been shown to undergo mesothelial to mesenchymal
transition under the influence of ovarian cancer cell secreted TGF-β, which can form a subpopulation
of the CAFs in ovarian cancer metastatic tumors [27]. Others have demonstrated that ovarian cancer
cells interact with the mesothelial cells in a β1-integrin-dependent manner to induce mesothelial to
mesenchymal transition and convert them into CAFs [28].
3. CAF Markers
Since CAFs in the tumor microenvironment are functionally very similar to the activated
fibroblasts in healing wounds, they both share several markers. CAFs express α-SMA, which is
also a marker of myofibroblasts in wound healing [10]. Ovarian cancer CAFs also express α-SMA,
while normal fibroblasts do not [29]. However, the expression of α-SMA is only one of many changes
that occur in activated fibroblasts [30]. The levels of expression of α-SMA may also vary between
CAFs. As evidenced by the findings of Mhawech-Fauceglia et al., the CAFs in ovarian tumors are
predominantly α-SMA positive, but not all of them stain for the protein [29]. This indicates the
existence of a certain level heterogeneity within the CAF population.
In addition to α-SMA, many other markers have been reported to distinguish CAFs from normal
fibroblasts. They include fibroblast activated protein (FAP), S100A4, and platelet derived growth
factor receptor, among others [7,29,31]. FAP, a cell surface serine protease, has emerged as a specific
marker of CAFs in ovarian cancer [32]. While each of them has been shown to be an effective marker
by different groups, there is no clear consensus about a universal marker for CAFs. The probable
reason for this is that CAFs are a heterogeneous population, with some expressing one marker and
others expressing other markers. α-SMA and PDGF positive CAFs do not overlap with S100A4
positive CAFs in pancreatic cancer [33]. The mutual exclusivity and heterogeneity in CAF marker
expression may impart unique functions; for example, FAP and podoplanin positive CAFs were found
to be immunosuppressive through a nitric oxide-dependent mechanism, while FAP positive and
podoplanin negative CAFs were not immunosuppressive in lung adenocarcinoma [34]. For prostate
cancer, CAFs expressing high CD90 had greater tumor promoting capacity than CAFs expressing low
CD90 [35]. Pancreatic ductal adenocarcinomas have a subpopulation of CAFs that are distinct from
those expressing α-SMA. These CAFs express proinflammatory mediators like IL-6, and mediate a
paracrine interaction with the carcinoma cells [36]. In ovarian cancer, the expression levels of different
CAF markers, CD10, podoplanin, FAP, Platelet-derived growth factor receptor alpha (PDGFRα),
Platelet-derived growth factor receptor beta (PDGFRβ), S100 calcium binding protein A4 (S100A4),
α-SMA, snail family transcriptional repressor 2 (SNAI2, commonly known as Slug), Zinc finger
E-box-binding homeobox 1 (ZEB1), and twist family bHLH transcription factor 1 (TWIST1), clustered
the CAFs into different subgroups showing different protein expression patterns [31].
Due to the continuous reciprocal interactions of CAFs with cancer cells, it is quite possible that
the CAFs can undergo dynamic changes in their marker expression and functions depending on the
heterogeneity of the cancer cells within the tumors. A recent study identified a unique subset of CAFs
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expressing the metallo-endopeptidase CD10 and the complement anaphylatoxin receptor GPR77 [37].
These CAFs were enriched following neoadjuvant chemotherapy, and were shown to promote cancer
stem cell self-renewal through the secretion of IL-6 and IL-8. Therefore, their abundance in the tumors
of breast cancer patients predicted a poor prognosis. Similarly, the evolving ovarian cancer metastatic
tumors are metabolically reprogrammed by CAFs through the secretion of C-C Motif Chemokine
Ligand 5 (CCL5), C-X-C motif chemokine ligand 10 (CXCL10), and IL-6 to utilize glycogen [38].
The CAFs with activated p38 MAP kinase signaling were capable of inducing such reprogramming.
Therefore, considering the heterogeneity of CAFs, it is important to take into account their functional
effects in promoting tumor progression as well as the potential of dynamic changes in them.
4. CAF Functions
CAFs have multiple functions in the tumor microenvironment, which directly or indirectly
promote tumor progression. Most of these functions are mediated through the secretion of paracrine
factors, ECMs, and proteases, as well as through cell surface receptors and direct contact with cancer
cells. These functions and their underlying mechanisms are detailed below, outlined in Figure 2,
and listed in Table 1.
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Figure 2. Functions of CAFs contributing towards tumor progression. ECM: extra cellular matrix; EMT:
epithelial–mesenchymal transition.
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Table 1. Functional roles of cancer associated fibroblasts (CAFs) in tumor progression.
No. Functional Role of CAF References
1 Promoting of tumor growth [39]
2 Promoting tumor invasion [3,40]
3 Inducing EMT in cancer cells [41,42]
4 Remodeling the ECM [43,44]
5 Inducing angiogenesis [45,46]
6 Inflammation and immune modulation [7,47]
7 Promoting chemoresistance and cancer stem cells [48,49]
8 Reprogramming cancer metabolism [3,4,38]
ECM: extra cellular matrix; EMT: epithelial–mesenchymal transition.
4.1. Promoting Tumor Growth
CAFs have predominantly been demonstrated to have tumor-promoting functions. They stimulate
cancer cell survival, growth, and invasion, enhance the stiffness of the extracellular matrix, contribute to
angiogenesis by releasing pro-angiogenic factors, contribute to a pro-inflammatory milieu, and impact
on the activation state of various immune cells [50]. CAFs are crucial in tumor-stroma communication
through modulation of the extracellular matrix, fibrogenesis, and chemoattraction of other stromal
cells. Several studies have demonstrated that tumor–CAF crosstalk promotes growth and invasion
of the particular cancer cells [39]. CAFs produce autocrine and paracrine cytokines that promote
the growth and biological characteristics of tumors [7]. In addition to classical growth factors,
including EGF and hepatocyte growth factor (HGF), novel CAF secreted proteins (secreted frizzled
related protein 1, and IGF like family member (IGF) 1 and 2) and membrane molecules (integrin
α11 and syndecan 1) have also been identified to possess cancer cell supporting roles. These factors
directly or indirectly stimulate tumor growth and survival, or enhance their migratory and invasive
properties [51]. Several secreted molecular regulators of CAFs have a pro-tumorigenic role, such as the
TGF-β superfamily and bone morphogenic proteins (BMPs), PDGFs, EGFs, fibroblast growth factors
(FGFs), and sonic hedgehog (SHH) [52].
Initial experiments with co-injection of CAFs with simian virus 40 (SV40)-transformed prostate
epithelial cells in mice resulted in tumors resembling prostatic intraepithelial neoplasia, whereas
normal fibroblasts did not. Similarly, co-transplantation of myofibroblasts with Ras-transformed
hepatocytes strongly enhances tumor growth through the TGF-β/PDGF axis [39]. In addition, CAFs
induce forkhead box Q1 (FOXQ1) expression; as a result, N-myc downstream-regulated gene 1
(NDRG1) is trans-activated to enhance hepatocellular carcinoma (HCC) initiation. Interestingly,
pSTAT6/CCL26 signaling is induced by the FOXQ1/NDRG1 axis, thus recruiting hepatic stellate cells
(HSCs), the main cellular source of CAFs, to the tumor microenvironment. Thereby, tumor-initiating
properties are enhanced at least partly through a positive feedback loop between CAFs and HCC
cells [53]. Taken together, these indicate that CAFs can provide growth-promoting signals to epithelial
cells, and support epithelial transformation [54].
Tumor-derived TGF-β1 has been reported to activate tumor stroma, and thereby facilitate
tumor growth and progression. Inhibition of the TGF-β pathway in mouse fibroblasts through
conditional inactivation of the TGFBR2 gene is associated with increased oncogenic potential of the
adjacent epithelia [55]. An invasive breast cancer cohort study, using a randomized tamoxifen trial,
demonstrated that TGF-β receptor type-2 expression in cancer-associated fibroblasts regulates breast
cancer cell growth and survival, and is a prognostic marker in pre-menopausal breast cancer [56].
Mesenchymal stem cell derived CAFs recruited to the stroma of the dysplastic stomach express
IL-6, Wnt5a, and bone morphogenetic protein 4, which promote tumor growth through DNA
hypomethylation [57]. In oral squamous cell carcinoma (OCC), CAFs promote the production of
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endogenous reactive oxygen species (ROS) through CCL2 expression, which induces the cell cycle
regulatory proteins, and promotes OCC proliferation, migration, and invasion [58]. CAFs have
also been reported to promote Th2 polarization of the tumor microenvironment, and stimulate
tumor growth and metastasis by recruiting tumor-associated macrophages (TAMs), myeloid derived
suppressor cells (MDSCs), and T regulatory cells (Tregs) [8,59].
In ovarian cancer, CAFs promote tumor invasion and growth through the secretion of a number
of chemokines, cytokines, and growth factors like CCL5, IL-6, IL-8, HB-EGF, and TGF-α, among
others [7]. These secreted factors were regulated by the decreased expression of miR-214 and miR-31,
and an increased expression of miR-155, in CAFs induced by ovarian cancer cells. CCL5 was a target
of miR-214 and miR-31, and was responsible for homing of the ovarian cancer cells onto plugs of CAFs
in vitro [7]. Inhibiting CCL5 with a neutralizing antibody was sufficient to reduce tumor growth of
co-injected CAFs and ovarian cancer cells in mice [7].
4.2. Promoting Tumor Invasion
Tumor invasion is a key hallmark of cancer and is essential for successful dissemination of the
cancer cells. Myofibroblasts have the inherent ability to invade through the ECM in the basement
membrane during wound healing. Similarly, CAFs have the ability to invade through matrix,
and have been widely reported to promote invasiveness of cancer cells [3]. There are several
potential mechanisms by which CAFs can directly or indirectly promote cancer cell invasiveness.
These include secretion of factors and proteases that help in the invasion. Zhu et al. (2016) [40] reported
that Gal-1-regulated CAF activation promotes breast cancer cell metastasis by upregulating MMP-9
expression in breast cancer. Recent studies have shown that breast CAFs overexpress the chemokine
CXCL1, a key regulator of tumor invasion and chemo-resistance. TGF-β negatively regulates CXCL1
expression in CAFs through Smad2/3 binding to the promoter, and through suppression of HGF/c-Met
autocrine signaling [60]. CAFs can also induce changes in the cancer cells, which helps in their
invasiveness. They have been reported to promote the metastatic activity of breast cancer cells by
activating the transcription of HOTAIR via TGF-β1 secretion [61].
CAFs can serve as engines for collective invasion of directly interacting cancer cells through
heterotypic interactions between the N-cadherin expressed on CAFs with the E-cadherin on cancer
cells [62]. Interestingly, a dual mechanism is involved. CAFs favor invasion of cancer cells by
pulling them away from the tumor, while cancer cells further enhance their spread by polarizing CAF
migration away from the tumor. Along similar lines, vimentin is reported to be necessary for lung
adenocarcinoma metastasis by maintaining heterotypic tumor cell–CAF interactions during collective
invasion [63]. Cdc42EP3—a member of the BORG family of Cdc42 effectors—is highly expressed in
CAFs, and regulates the actin and septin fibrillar networks. Coordination between the actin and the
septin networks in CAFs is required for force-mediated matrix remodeling, promoting cancer cell
invasion, angiogenesis, and tumor growth [64].
In ovarian cancer we have previously shown that CAFs can promote coordinated invasion of the
cancer cells, which promotes metastasis [7]. Using a novel 3D live confocal imaging-based co-invasion
assay, we observed that the CAFs derived from ovarian cancer omental metastasis are able to closely
interact with ovarian cancer cells and invade through matrigel by forming distinct networks of CAFs
and cancer cells, which invaded together. Cancer cells alone invaded at a slower rate and failed to form
the network consisting of cellular associations. The mechanism of CAF–cancer cell interactions reported
by Labernadie et al. [62] involving heterophilic E-cadherin/N-cadherin junctions could potentially be
playing a role in these interactions between the CAFs and ovarian cancer cells. A comparison of gene
expression profiles of CAFs from omental metastasis with normal omental fibroblasts revealed that the
CAFs secrete multiple chemokines and cytokines that can potentially regulate invasion and motility
of cancer cells [7]. Among them, CCL5 was identified as a key CAF derived mediator of metastasis,
which was itself regulated by miR-214 and miR-31. Both these microRNAs are downregulated in CAFs
during the reprogramming of normal fibroblasts by metastasizing ovarian cancer cells [7]. Zhao et al.
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(2017) identified STAT4 as a key regulator of ovarian cancer metastasis via Wnt7a-induced activation
of CAFs [65]. The concomitant increased production of CXCL12, IL6, and VEGFA by CAFs within
the tumor microenvironment could enable peritoneal metastasis of ovarian cancer via induction of
the EMT program. They also established a model of promotion of ovarian cancer metastasis by
STAT4 via tumor-derived Wnt7a-induced activation of CAFs [65]. CAFs promote ovarian cancer
cell proliferation, migration, and invasion through the paracrine FGF-1 factor. The FGF-1/FGFR-4
signaling axis regulates the stromal microenvironment in ovarian carcinomas. CAFs also activate the
expression of Snail1 and MMP3, as well as reduce the expression of E-cadherin [66].
4.3. Inducing EMT in Cancer Cells
An epithelial-mesenchymal transition (EMT) is a biological process that allows a polarized
epithelial cell, which normally interacts with the basement membrane via its basal surface, to undergo
multiple biochemical changes that enable it to assume a mesenchymal cell phenotype, which includes
enhanced migratory capacity, invasiveness, elevated resistance to apoptosis, and greatly increased
production of ECM components. The completion of an EMT is signaled by the degradation of the
underlying basement membrane and the formation of a mesenchymal cell that can migrate away from
the epithelial layer in which it originated [67]. The idea that epithelial cells can downregulate epithelial
characteristics and acquire mesenchymal characteristics arose in the early 1980s from observations
made by Elizabeth Hay [68]. Over the subsequent years, the importance of EMT in cancer progression
has been well established. The heterotypic interactions of cancer cells with the microenvironment,
including CAFs, has been shown to be a key inducer of EMT.
Coculturing CAFs with lung cancer cells can induce miR-33b downregulation and promote
epithelial cells EMT. miR-33b overexpression in lung cancer cells can counteract CAF-induced EMT.
Interestingly, Snail1 expression in fibroblasts activates the inductive effects of CAFs on lung cancer
cells. Snail1-expressing cancer-associated fibroblasts induce lung cancer cell epithelial-mesenchymal
transition through miR-33b [41]. CAF conditioned medium induced epithelial-mesenchymal
transition (EMT) by regulating the expression of EMT-associated markers E-cadherin and vimentin,
and modulated metastasis-related genes MMP-2 and VEGF, both in vitro and in vivo. Further studies
demonstrated that CAFs enhanced the metastatic potential of lung cancer cells by secreting IL-6 and
subsequently activating the JAK2/STAT3 signaling pathway [42]. TGF-β1 secreted by CAFs can
induce EMT in the interacting cancer cells and promote metastasis [69,70]. In ovarian tumors, CAF
derived exosomes contain higher levels of TGF-β1 compared to those derived from normal omental
fibroblasts [71]. Theses exosomes, upon uptake by ovarian cancer cells, induce EMT through the
activation of SMADs. Activation of STAT3 by microenvironmental IL-6 can also induce EMT in ovarian
cancer cells [72]. CAFs were reported to be the major source of IL-6 in the tumor microenvironment of
ovarian tumors [72]. Therefore, CAFs can make cancer cells more aggressive by inducing EMT in them
through various paracrine mechanisms.
4.4. Remodeling the ECM
Every organ has an ECM with unique composition, providing physical support for tissue integrity
and elasticity. It is a dynamic structure that is constantly remodeled to control tissue homeostasis [73].
Dysregulation of ECM composition, structure, stiffness, and abundance contributes to several
pathological conditions, such as fibrosis and invasive cancer. Typically, tumors have much stiffer ECMs,
causing altered dynamics of the biophysical and biochemical interactions of the cancer cells with their
microenvironment [74]. The increased stiffness of the matrix promotes invasiveness and motility of the
cancer cells through improved invadosome and lamella formation [75]. Matrix stiffness drives EMT and
metastasis through the TWIST1–G3BP2 mechanotransduction pathway in breast cancer [76]. A 9-gene
matrisome gene signature has been identified through the analysis of available databases, and is
associated with tumor progression through promotion of EMT, angiogenesis, hypoxia, inflammation,
and altered metabolism in several cancers, including ovarian cancer [43]. Altered ECMs and ECM
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remodeling enzymes, like matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases
(TIMPs), and lysyl oxidases (LOXs), work to create a stiffer microenvironment permissive for tumor
cell growth, migration, and invasion [44]. The increased secretion of fibronectin and LOXs by breast
cancer CAFs contribute towards the remodeling of the ECMs in these tumors, promoting invasion and
metastasis [77]. TGF-β activates the secretion of versican by CAFs in high-grade serous ovarian tumors,
which induces the expression of MMP9 and CD44 by the cancer cells, resulting in ECM remodeling
and invasion [78]. A recent study has demonstrated the role of ovarian cancer cell derived inhibin βA
in effectively inducing CAFs, which then secrete increased amounts of collagens and other ECMs [79].
Therefore, CAFs serve the important function of remodeling the ECMs through altered secretion of the
matrisome components, and provide the ideal microenvironmental stiffness for tumor progression.
4.5. Inducing Angiogenesis
As the tumor grows, the cancer cells are further removed from the existing blood vessels, and as
a result, experience depleted levels of oxygen and nutrients. This typically places a limit to the
tumor size, as cell proliferation in the regions well supplied by the blood vessels is balanced by cell
death in the regions deprived of oxygen and nutrients. Therefore, in order to progress, the tumors
must induce angiogenesis. It is the formation of a new vascular network to supply nutrients and
oxygen, and remove waste products. Multiple factors, like VEGF, basic fibroblast growth factor (bFGF),
interleukin-8 (IL-8), placenta-like growth factor (PLGF), TGF-β, platelet-derived endothelial growth
factor (PD-EGF), pleiotrophin, activated hypoxia-inducible factor-1α (HIF-1α), and so forth, have been
shown to trigger angiogenesis [80,81]. Many of these pro-angiogenic factors are contributed by the
tumor microenvironment [82]. CAFs induce angiogenesis directly, as well as indirectly, through VEGFA,
PDGFC, FGF2, CXCL12, osteopontin, and CSF3 secretion, ECM production, and recruitment of myeloid
cells [82]. SDF-1 secreted by breast cancer CAFs has been involved in mobilization of endothelial
precursor cells from bone marrow, thereby inducing de novo angiogenesis, as well as in tumor growth
through a paracrine effect on CXCR4 expressing cancer cells [45]. Similarly, fibroblast-derived SDF-1
synergized with IL-8 in the promotion of a complete angiogenic response in recruited endothelial
cells in pancreatic cancer [46]. SDF-1 is induced in breast cancer CAFs by oxidative stress-mediated
activation of HIF-1 [83]. Chloride intracellular channel protein 3 (CLIC3) secreted by breast cancer
CAFs induces angiogenesis through an active transglutaminase-2 (TGM2) mediated mechanism [84].
MMP-13 secreted by CAFs promotes tumor angiogenesis by releasing VEGF entrapped in the
ECM, thereby leading to increased invasion of endothelial cells in squamous cell carcinoma and
melanoma [85]. Ovarian cancer CAFs can indirectly induce angiogenesis through increased secretion
of pro-inflammatory factors IL-6, COX-2, and CXCL1 [86]. Ovarian cancer cell expression HOXA9
induces CAFs to secrete CXCL12, IL-6, and VEGF-A expression, which promotes angiogenesis [87].
Ovarian cancer CAFs have also been shown to induce angiogenesis by secreting VEGF-C as a result
of induction by Sonic Hedgehog (SHH) from ovarian cancer cells [88]. While angiogenesis can be
induced by cancer cells as well as the tumor microenvironment, CAFs are important direct or indirect
contributors to the process, and hence towards cancer progression.
4.6. Inflammation and Immune Modulation
Inflammation is a normal physiological response that is initiated in injured tissue and helps in its
healing. In clinical settings, chronic inflammation and cancer are closely related, and cancer is referred
to as “wounds that never heal”. During tissue injury associated with wounding, cell proliferation is
enhanced while the tissue regenerates; proliferation and inflammation subside after the assaulting
agent is removed or the repair completed. In contrast, proliferating neoplastic cells continue
to proliferate in microenvironments rich in inflammatory cells, and growth and survival factors,
that support their growth [89]. Pro-inflammatory cytokines are secreted by cancer cells and CAFs
to attract immune cells to the tumor. Macrophages actively attracted into tumor regions along
defined chemotactic gradients start to differentiate into tumor-associated macrophages (TAMs),
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which further enhance the growth and metastasis of cancer cells [52]. CAFs are functionally required
for mediating inflammation during squamous cell carcinogenesis, starting at the earliest pre-neoplastic
stages [90]. A recent paper demonstrated that CAFs associated to incipient neoplasia exhibit a
pro-inflammatory signature, leading them to mainly overexpress SDF-1, IL-6, and IL-1β, as well
as to recruit proangiogenic macrophages. This gene set is under the transcriptional control of nuclear
factor-κB (NF-κB) and cyclooxygenase 2 (COX-2), thereby strengthening the link between CAFs
and inflammatory mediators in tumor progression [47]. We have demonstrated that ovarian cancer
CAFs produce an array of chemokines and cytokines, which can potentially induce a proinflammatory
response [7]. These chemokines and cytokines were directly or indirectly regulated by miR-214, miR-31,
and miR-155 in CAFs [7]. Several other groups have also shown many chemokines and cytokines,
including IL-6, COX-2, and CXCL1, to be involved in tumor-related inflammation in epithelial ovarian
cancer [50,91].
CAFs in the tumor microenvironment exert immunomodulatory effects through secretion of
immunomodulatory factors that polarize responsive immune populations, such as macrophages [92].
In order for the tumor to survive, any immune response directed toward the tumor cells needs
to be suppressed [52]. CAFs play important roles in shaping the tumor immunosuppressive
microenvironment in oral squamous cell carcinoma by inducing the protumor M2 macrophages [93].
Immunosuppressive activity of CAFs has been reported in head and neck squamous cell carcinoma
through increased expression levels of IL-6, CXCL8, and TGF1 [94]. Genetic ablation of
Chitinase 3-like 1 (Chi3L1) in fibroblasts in vivo attenuated tumor growth, macrophage recruitment,
and reprogramming to an M2-like phenotype, enhanced tumor infiltration by CD8+ and CD4+ T cells,
and promoted a Th1 phenotype. These results indicate that CAF-derived Chi3L1 promotes tumor
growth and shifts the balance of the immune milieu towards type 2 immunity [95]. Activation of
the PD1/PDL1 signaling pathway in T-cells leads to T-cell exhaustion and immune suppression. IL6
secreted by CAFs in hepatocellular carcinoma activates neutrophils in the tumor microenvironment,
and induces PDL1 expression in them through the JAK-STAT3 pathway. The PDL1 expressing
neutrophils inhibit T-cell mediated immunity and create a protumor microenvironment [96]. Being the
most abundant cellular component of the stroma, CAFs can exert their effects indirectly on tumor
progression through secreted factors that help evolve a proinflammatory and immunosuppressive
microenvironment for the cancer cells to thrive in.
4.7. Promoting Chemoresistance and Cancer Stem Cells
The eventual development of chemoresistance is the cause of most ovarian cancer related
mortalities. The role of the tumor microenvironment in this process has generated great interest
in recent years. Glutathione and cysteine released by fibroblasts in ovarian tumors contribute
towards the depletion of platinum in the nuclei of the adjacent ovarian cancer cells, and thus impart
resistance to platinum based chemotherapies [97]. CAFs can also induce therapy resistance by
reducing the bioavailability of the drugs, by causing tumor microvessel leakiness. CAFs induce
the lipoma-preferred partner (LPP) gene in microvascular endothelial cells through a calcium-dependent
FAK/ERK/MLC2/CREB signaling pathway [48]. In one study, the increased LPP enhanced
the endothelial cell motility and permeability through increased focal adhesions and stress fiber
formation [48]. CAFs can also induce chemoresistance in cancer cells by inducing apoptosis resistance.
CAFs activate STAT3 signaling in ovarian cancer cells resulting in the development of chemoresistance
through the increased expression of the antiapoptotic survivin and Bcl-2 [49]. CAFs in pancreatic ductal
adenocarcinoma can similarly decrease apoptosis and increase the chemoresistance of the cancer cells
by the induction of transcriptional downregulation of caspases by promoter hypermethylation [98].
Ovarian cancer apoptosis was also inhibited by CAF derived exosomes that transfer miR-21 to the
cancer cells. The miR-21 then downregulated its direct target apoptotic protease activating factor 1
(APAF1), conferring chemoresistance [99].
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Cancer stem cells are known to be resistant to cytotoxic chemotherapy and can give rise to tumor
relapse. CD10 and GPR77 expressing CAFs induce cancer stem cells in breast and lung cancer through
the consistent secretion of IL-6 and IL-8 [37]. These CAFs also increase the take rate of patient derived
xenograft tumors, and inhibition of GPR77 abolishes this effect [37]. In one study, autophagic CAFs in
luminal breast cancer induced stemness in the cancer cells through the secretion of high-mobility group
box 1 (HMGB1), resulting in the activation of toll-like receptor 4 in the cancer cells [100]. In endocrine
resistant metastatic breast cancer, the transfer of CAF derived exosomes containing miR-221 activated
an ERlo/Notchhi feed-forward loop that generated CD133hi cancer stem cells [101]. In ovarian cancer,
the evidence of induction of cancer stem cells is limited, with a few reports indicating the role of
CAF derived fibroblast growth factor 4 and IL-6 in inducing cancer stem cells [102,103]. Targeting
the FHF4/FGFR2 axis that mediates the CAF-cancer stem cell signaling prevented the CAFs from
inducing cancer stem cells [102]. Insulin growth factor receptor activation in ovarian cancer cells by
CAFs, and the resulting increased Nanog expression, is also reported to promote cancer stem cells in
ovarian cancer [104]. Overall, the potential role of CAFs in providing a stem cell niche for cancer stem
cells is an idea that needs to be systematically researched.
4.8. Reprogramming Cancer Cell Metabolism
Cancer cells have an altered metabolism to cope with their different growth rate, nutrient
availability, and the hypoxia they experience as compared to normal cells. This altered metabolism is
considered one of the hallmarks of cancer, and the tumor microenvironment is a major contributor
towards this phenomenon [3,4,38,105]. CAFs have been reported to secrete vesicles, which created
hypoxia mimicking conditions in the cancer cells, causing reductive carboxylation of glutamine in
them, and decreased oxidative phosphorylation [106]. The CAF derived vesicles are also carriers
of metabolites feeding into the tricarboxylic acid cycle in the cancer cells. This brings forth a novel
mechanism by which CAFs can influence the cancer cells through the transfer of metabolites and
pushing away from an oxygen based energy metabolism. Using stable isotope labeling of amino acids
in cell culture (SILAC) in cocultures of CAFs with ovarian cancer cells, a recent study demonstrated
how the CAFs can help ovarian cancer cells switch from utilizing lipids to using glycogen reserves
for energy [38]. As the metastatic tumor grows and depletes the adipocytes in the omentum, the IL-6,
CXCL10, and CCL5 secreted by the CAFs induce the ovarian cancer cells to start utilizing glycogen.
The activation of p38 MAP kinase in the CAFs drives the cytokine secretion, which in turn activates
glycogen phosphorylase in the ovarian cancer cells [38]. This demonstrates that the dynamic changes
happening in the tumor microenvironment as the tumor progresses, forces the cancer cells to reset
their energy sources. CAFs can orchestrate this switch by turning off glycogen synthesis and activating
glycogen utilization for glycolysis. Therefore, targeting the key enzyme in this process, glycogen
phosphorylase, would be a potential therapeutic option to treat ovarian cancer metastasis.
5. Targeting CAFs Clinically
Since CAFs contribute towards so many critical aspects essential for tumor progression, strategies
targeting CAFs to treat ovarian cancer can be potentially effective. Moreover, since CAFs themselves
are genetically stable and do not have the propensity to mutate, acquiring resistance against these
therapies would be less likely. Since CAFs overexpress FAP, a humanized antibody (sibrotuzumab)
directed against human FAP has been tested in phase 1 clinical trials to demonstrate that it is safe to
administer to patients with high levels of FAP expression in their tumors [107]. However, it did not
have any beneficial effect in a phase II trial for metastatic colorectal cancer [108]. A fusion protein
consisting of an anti-FAP antibody fused with IL-2 (RO6874281) is presently under clinical trials
as a combination therapy with atezolizumab—an anti-PDL-1 antibody—for advanced or metastatic
solid tumors (ClinicalTrials.gov: NCT03386721). In addition, a phase I clinical trial is ongoing to
test RO6874281 as a single agent, or in combination with trastuzumab or cetuximab, for solid tumor,
and breast, head, and neck tumors (ClinicalTrials.gov: NCT02627274). As TGF-β plays an essential
Cancers 2018, 10, 406 12 of 18
role in stromal-epithelial interaction and CAF induction, targeting TGF-β is a potentially promising
approach to target CAFs as well as cancer cells. Transgenic mice expressing a TGF-β antagonist were
resistant to metastasis to multiple organs while not exhibiting the adverse pathological outcomes
observed in TGF-β-null mice [109]. Transcription profiling of CAFs microdissected from ovarian cancer
patient tumors identified a subpopulation that had activation of SMAD signaling [110]. These CAFs
were markers of poor patient progression, and targeting SMAD signaling with calcitriol inhibited
tumor progression in mice. At present there are as many as 60 active clinical trials on TGF-β in cancers
(clinicaltrials.gov). However, it is very difficult to differentiate the role of CAF derived TGF-β from
other stromal sources and cancer cell autocrine TGF-β signaling. The HGF-cMet pathway, involving
the cross-talk between CAFs and cancer cells, plays a role in cancer metastasis, and is another potential
target for blocking CAF–cancer cell interaction. Targeting c-Met or HGF has shown promising tumor
growth inhibition and gemcitabine sensitization in vivo [111,112]. There are 69 active studies on cMet
listed in clinicaltrials.gov. Targeting CAF can decrease the immunosuppressive microenvironment of
the tumor, as well as lead to CD8+ T-cell activation, and enhance anti-tumor immunity [18,113].
While several strategies to target CAFs in tumors have been attempted, much remains to be
studied before it can be effectively translated to the clinic. Strategies like targeting TGF-β may benefit
from attacking both the cancer and stromal compartments. Importantly, the potential of combining
such therapies with existing platinum and taxane based chemotherapies should be tested for ovarian
cancer. However, previous experiences with targeting the tumor microenvironment have taught us
that an approach towards normalization is preferable to an eradication of the tumor stroma. This is
because the latter approach tends to give rise to more aggressive cancer cells. Therefore, targeting
CAFs should aim for reverting them back to normal fibroblasts, rather than depleting them altogether.
6. Conclusions
CAFs are an important constituent of the ovarian cancer tumor microenvironment, and have been
demonstrated to play an important role in tumor progression, metastasis, and chemoresistance. While a
universal CAF marker has not been identified, several markers have been demonstrated in unique
subpopulations, indicating that CAFs are heterogenous in this context, and this may also dictate their
function. Continuous reciprocal interactions of CAFs with cancer cells and other components of the
microenvironment shape their fate, marker expression, and function in the tumor. Continuing research
towards a better understanding of their plasticity, regulation, function, and heterogeneity would
greatly enhance the way we perceive tumors, and will determine how we treat them. Strategies to
“normalize” CAFs and deprive the cancer cells of the gamut of factors provided by them may be an
effective approach to complement existing therapies targeting the cancer cells.
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